Navigation Links
Epi-K

ProductsEpi-K
Company Moria S.A.
Item Epi-K
Features 
  • Precision machining produces a uniform, reproducible, metal blade separator.
  • Angle of blade to epithelium allows for cleavage of the epithelial layer instead of cutting.
  • Cleavage follows along plane of least resistance by separating and rupturing this plane.
  • Cleavage at the level of the basement membrane appears to allow for a viable epithelial layer.
  • Presence of an applanation front plate prevents cutting into the stroma.
  • Implication of potential better wound healing:
    • less apoptosis (more stable result).
    • possibly less pain.
  • Expected more rapid visual recovery.
Description The Epi-K is a fully automated system with a disposable head that enables surgeons to perform a new refractive procedure known as Epi-Lasik. The Epi-K is utilized to mechanically cleave the epithelium from the Bowmans membrane leaving a pristine optical zone for laser ablation. Epi-Lasik preserves the structural integrity of the stroma and is expected to minimize discomfort, shorten the length of visual recovery, and reduce the incidence of haze associated with other surface ablation procedures, such as PRK and LASEK.
Info Moria S.A.
Customer Service: (215) 230 - 7662
Web site: http://www.moria-surgical.com

Related medicine products :

1. Centurion SES Epikeratome
TAG: Epi
Budde retractor blades are designed for the retraction of nerves, vessels, delicate tissue and basal lesions, as well as brain retraction. Equalized brain retraction pressure. Decreased shear injury
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us
Cone Ring Curettes, length 9" (229 mm), ring diameter (I.D.) 5/16" (8 mm).
Scoville Ruptured Disc Curettes, length 10" (254 mm), cup size 4 x 10 mm.
Medicine Products:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...esearch, caries in primary teeth may cause develop...oth can have caries for a wide variety of reasons ...onomic status, years of exposure to water fluorida...early loss of primary teeth. Accounting for all th...
...event or treat chronic lung disease may result in ...school age say researchers based on findings of a ... dexamethasone, a drug known as glucocorticoid, of...d allows for early weaning from mechanical ventila...
...seen that the frequency of withholding or withdraw...atient’s life varies greatly among European countr...ovided unprecedented opportunities in diagnostics ...in some situations at the end of a patient’s life,...
... World Health Organization (WHO) and the United Na...that there is almost a 50% drop of measles death ...ed to the successful vaccination programme being u...vaccine-preventable condition. Global measles deat...
Other Medicine News:Health News:Drop in Worldwide Measles deaths by 40% 2
(Date:10/7/2008)...INS, Colo., Oct. 7 /- A study publish...yonic stem cell self-renewal,reported that InVitr...inant,human serum albumin) was an effective replac... The article entitled, "The ground state of embry...rchers used Cellastim as a recombinant,albumin in ...
(Date:10/7/2008)..., Mass., Oct. 7 /- Taligen Therapeuti...al of the Company,s pipeline,candidates were prese... in,Basel, Switzerland. The data highlighted the c...mplement-mediated diseases., "These highlighted p...presented at the conference, reveal the deep exper...
(Date:10/7/2008)...bstracts highlighting CIMZIA,s long-term benefits ...tients presented at American College,of Gastroente...rstCall/ -- Data from two studies,presented this w...logy,(ACG) Annual Meeting demonstrate that CIMZIA(...TNF alpha (Tumor Necrosis Factor alpha) - provides...
(Date:10/7/2008)..., Oct. 7 /- Ardea Bioscienc...oster entitled "RDEA119, a Potent,and Highly Selec...fate,Sodium (DSS) -- induced Chronic Colitis in Mi...roenterology (ACG) 2008 Annual Meeting in Orlando,...reclinical study of,RDEA119, the Company,s lead mi...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Studies Reveal Why Breast Cancer Hits Black Women Harder 7238 1Studies Reveal Why Breast Cancer Hits Black Women Harder 7238 2Studies Reveal Why Breast Cancer Hits Black Women Harder 7238 3Stroke study to add patients who cannot give immediate consent 7234 1Stroke study to add patients who cannot give immediate consent 7234 2Stroke study to add patients who cannot give immediate consent 7234 3Irene Hegeman Richard MD Appointed Senior Medical Advisor to The Michael J Fox Foundation 7230 1Irene Hegeman Richard MD Appointed Senior Medical Advisor to The Michael J Fox Foundation 7230 2Malaria Community Applauds Clintons 241 Billion a Year Pledge 3B Invites Other Candidates to Make Malaria Commitments 7226 1Malaria Community Applauds Clintons 241 Billion a Year Pledge 3B Invites Other Candidates to Make Malaria Commitments 7226 2Malaria Community Applauds Clintons 241 Billion a Year Pledge 3B Invites Other Candidates to Make Malaria Commitments 7226 3
...rQule, Inc.,(NASDAQ: ARQL) today announced that th... accepted for oral presentation the,Company,s abst...of,ARQ 197, a Selective Inhibitor of the c-Met Rec... the 43rd ASCO Annual Meeting, June,1-5, 2007, in ...from a Phase 1 trial with ARQ 197, a selective, sm...
...II Trial Results,For Novel Oral Thrombin Receptor ...can College Of Cardiology/i2 Summit, KENILWORTH, N...ring-Plough Corporation announced today that resul...n receptor antagonist (TRA),SCH 530348 will be pre...he of Cardiology (ACC.07)/Innovation in Interventi...
Other Medicine Technology:ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 2ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 4Media Advisory: ACC Updated Schedule 2